Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant - Pharmaceutical Technology

Vivani’s NanoPortal technology delivers medication steadily over long periods of time. Vivani’s NanoPortal technology delivers medication steadily over long periods of time. For Novo Nordisk, the pact with Vivani is another push to fend off increasing pressure from rivals. Credit: Kittyfly/Shutterstock.com. Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off market rivals. Novo has signed an agreement with Vivani that will allow it to evaluate NPM-139, a long-lasting semaglutide drug implant in development for chronic weight management. NPM-139 is a miniature subdermal implant…

Source: Pharmaceutical Technology